Resumen
La relación entre las enfermedades inmunológicamente mediadas del sistema nervioso central (SNC) y las infecciones es muy estrecha. En primer lugar, es importante reconocer que las infecciones pueden desencadenar reacciones inmunopatológicas que pueden conducir posteriormente a la manifestación de enfermedades neurológicas. En segundo lugar, las infecciones se han reconocido como complicación de algunas de las terapias empleadas para tratar condiciones neurológicas que requieren cierto grado de inmunosupresión. Las estrategias de mitigación de riesgo (EMR) son muy importantes para prevenir complicaciones asociadas con los tratamientos farmacológicos, así como generar estrategias de prevención con respecto a inmunización y detección del perfil de riesgo, antes del inicio de terapias.
Citas
Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML. Challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88:1-9. doi: 10.1212/WNL.0000000000003739.
Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber Hanselmann S, Hemmer B, Berthele A. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? Neurology. 2016;87(4):440-1. doi: 10.1212/WNL.0000000000002900.
Arvin A, Wolinsky J, Kappos L, Morris M, Reder A, Torna-tore C, Gershon A, Gershon M, Levin M, Bezuidenhoudt M. Putzki N. Varicella-zoster virus infections in patients treated with fingolimod risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31-9. doi: 10.1001/jamaneurol.2014.3065.
Pirttisalo, A, Sipilà, J, Viitala, M, Soilu-Hànninen, M. Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009-2018. Mult Scler Relat Disord. 2020;44. doi: 10.1016/j.msard.2020.102328.
Van Wijmeersch B, Singer B, Boster A, Broadley S, Fernández O, Freedman M, et al. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Mult Scler. 2020;26(13):1719-28. doi: 10.1177/1352458519881759.
Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK. Vaccination in multiple sclerosis: friend or foe? Front Immunol. 2019;10:1883. doi: 10.3389/fimmu.2019.01883.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R. Infections, vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines (Basel). 2020;8(1):50. doi: 10.3390/vaccines8010050.
Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68(10):1267-71. doi: 10.1001/archneurol.2011.131.
Oreja-Guevara C, Wiendl H, Kieseier BC, Airas L. Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Ther Adv Neurol Disord. 2014;7(2):137-49. doi: 10.1177/1756285613501575.
Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review Mult Scler Relat Disord. 2020;45:102439. doi: 10.1016/j.msard.2020.102439.
Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review PLoS One. 2013;8(7):e66308. doi: 10.1371/journal.pone.0066308.
Tolou-Ghamari Z. Efficacy and toxicity of rituximab in multiple sclerosis. Arch Neurosci. 2016;3(1):e30107.
Bigaut K, De Seze J, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2018;19(2):97-108. doi: 10.1080/14737175.2019.1561284.
Hauser S, Li D, Calabresi P, O'Connor P, Bar-Or A, Barkhof F, et al. Week 144 results of a phase II, randomized, multi-center trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) (S31.004). Neurology. 2013;80:S31.004.
Voge N, Alvarez E. Monoclonal antibodies in multiple sclerosis: present and future. Biomedicines. 2019;7(1):20. doi: 10.3390/biomedicines7010020.
Sorensen PS, Lisby S. Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573-81. doi: 10.1212/WNL.0000000000000125.
Bar-Or A, Grove RA, Austin D, Tolson J, VanMeter S, Lewis E, Derosier F, Lopez M, Kavanagh S, Miller A, Sorensen PS. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90(20):e1805-14. doi: 10.1212/WNL.0000000000005516.
Grebenciucova E, Pruitt A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep. 2017;17(11):88. doi: 10.1007/s11910-017-0800-8.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi: 10.1056/NEJMoa0909494.
Issa NP, Hentati A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology . 2015;84(1):99-100. doi: 10.1212/WNL.0000000000001109.
Behrangi N, Fischbach F, Kipp M. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells. 2019;8(1):24. doi: 10.3390/cells8010024.
Dumitrescu L, Constantinescu C, Tanasescu R. Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother. 2019;20(2):143-50. doi: 10.1080/14656566.2018.1551363.
Kappos L, Bar-Or A. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-73. doi: 10.1016/S0140-6736(18)30475-6.
Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology . 2007;68(24 Suppl 4):S8-11. doi: 10.1212/01.wnl.0000277703.74115.d2.
Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050-6. doi: 10.1136/jnnp-2017-317493.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-91. doi: 10.1001/jamaneurol.2019.3365.
Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol. 2008;255 Suppl 1:26-36. doi: 10.1007/s00415-008-1005-5.
Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2028;32(3):269-87. doi: 10.1007/s40263-018-0488-6.
Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal antibodies for multiple sclerosis: an update. BioDrugs. 2019;33(1):61-78. doi: 10.1007/s40259-018-0327-9.
Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2017;136(3):168-86. doi: 10.1111/ane.12712.
Drugs@FDA: FDA-Approved Drugs. [Internet]. Highlights of prescribing information, lemtrada. [aprox. 28 p]. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103948s5158lbl.pdf.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578-93. doi: 10.1177/1352458510391344.
McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27);734-7. doi: http://dx.doi.org/10.15585/mmwr.mm6627e1.
Drugs@FDA: FDA-Approved Drugs. [Internet]. Highlights of prescribing information, soliris. [aprox. 10 p]. Disponible en:https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf
Greenberg B, De Seze J, Fox E, Saiz A, Yamamura T, Marcillat C, et al. Safety of satralizumab based on pooled data from phase 3 studies in patients with neuromyelitis optica spectrum disorder (NMOSD) (1281). Neurology . 2020;94(15 Suppl).
Centers for Disease Control and Prevention (CDC) [Internet]. Recommended adult immunization schedule for ages 19 years or older, United States, 2020. Disponible en: https://wwwcdc.gov/vaccines/schedules/hcp/imz/adult.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fhcp%2Fadult.html.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-65. doi: 10.1016/S1474-4422(12)70310-1.
Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 1991;86(2):192-98. doi: 10.1111/j.1365-2249.1991.tb05794.x
Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 22;367(21):2015-25. doi: 10.1056/NEJMra1009433.
Suppiej A, Nosadini M, Zuliani L, Pelizza MP, Toldo I, Bertossi C, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review. Brain Dev. 2016;38(7):613-22. doi: 10.1016/j.braindev.2016.01.009.
Mokrzycki MH, Kaplan AA. Therapeutic plasma ex change: complications and management. Am J Kidney Dis. 1994;23(6):817-27. doi: 10.1016/s0272-6386(12)80135-1.
Picard N, Cresteil T, Prémaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004;26(6):600.8. doi: 10.1097/00007691-200412000-00004.
Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinet-ics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet. 2013;52(5):303-31. doi: 10.1007/s40262-013-0039-8.
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136-42. doi: 10.1016/0167-5699(92)90111-J.
Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506)-- a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992 Jun;128(6):781-5. 10.1001/archderm.1992.01680160065005
Astellas Pharma US. [Internet]. Highlights of prescribing information, prograf. [aprox. 52 p]. Disponible en: https://www.astellas.us/docs/prograf.pdf.
European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclo-sporin in prevention of liver allograft rejection. Lancet. 1994;344(8920):423-8.
Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. Treatment of Primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96 - 07. J Clin Oncol. 2003;21(6):1044-9. doi: 10.1200/JCO.2003.03.036.
Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012; 17(4): 550-4. doi: 10.1634/theoncologist.2011-0431.
Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NM-DAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11-8. doi: 10.1002/ana.21756.
Cristelli MP, Tedesco-Silva H, Medina-Pestana JO, Franco MF Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and cortico-steroids. Transpl Infect Dis. 2013;15(4):369-78. doi: 10.1111/tid.12095.
Randell RL, Adams AV, Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pediatr Neurol. 2018;86:66-8. doi: 10.1016/j.pediatrneu-rol.2018.07.016.
Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824-32. doi: 10.1007/s13311-016-0442-6.
de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology . 2019;92(19):e2185-96. doi: 10.1212/WNL.0000000000007475.
Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemo-therapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacar-bazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748-54. doi: 10.1200/JCO.2008.17.5448.
Andre P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial. Ann Pharmacother. 2005;39(9):1462-6. doi: 10.1345/aph.1E620.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bort-ezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117(10):2807-12. doi: 10.1182/blood-2010-11-314708.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology . 2020;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380.
Hua C, Barnetche T, Combe B, Morel J. Effect of metho-trexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-26. doi: 10.1002/acr.22246.
Farez MF, Correale J, Armstrong MJ, Rae-Grant A, Gloss D, Donley D, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology . Neurology . 2019;93(13):584-94. doi: 10.1212/WNL.0000000000008157.
Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A, von Rosenstiel P. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology . 2015;84(9):872-9. doi: 10.1212/WNL.0000000000001302.
Otero-Romero S, Rodríguez-García J, Vilella A, Ara JR, Brieva F, Calles C, et al. Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmu-nosupresoras: documento de consenso español. Neurología. 2020. doi: 10.1016/j.nrl.2020.02.006.
Olberg HK, Eide GE, Cox RJ, Jul-Larsen A, Lartey SL, Vedeler CA, Myhr KM. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving im-munomodulatory therapy. Eur J Neurol. 2018;25(3):527-34. doi: 10.1111/ene.13537.
Metze C, Winkelmann A, Loebermann M, Hecker M, Schwei-ger B, Reisinger EC, Zettl UK. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving diseaseDmodi-fying therapies. CNS Neurosci Ther. 2019;25(2):245-54. doi: 10.1111/cns.13034.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology . 2020;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380.
Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence [Internet]. Disponible en: https://www.cdc.gov/mmwr/preview/mmwrht-ml/00023141.htm.
Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis. 2013;57(6):849-52. doi: 10.1093/cid/cit376.
Sanofi U.S. [Internet]. Highlights of prescribing information, alemtuzumab. [aprox. 35 p]. Disponible en: http://products.sanofi.us/Lemtrada/Lemtrada.pdf ?s_mcid=ps-LP-google-BRsitelink-pi
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.